Second-line treatment of postmenopausal women with advanced breast carcinoma.
Breast cancer is the most prevalent cancer in women and, currently, there is no standard of care for the treatment of metastatic disease. Treatment options are based on a number of tumor- and patient-related factors. This review explores some of these options, including the use of hormonal manipulation in the treatment of hormone-positive disease, current chemotherapy options and the use of targeted therapies, such as trastuzumab.
Board
Ruth E
RE
Cancer Research UK Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. ruth.board@christie-tr.nwest.nhs.uk
Dean
Emma J
EJ
Mitchell
Claire
C
Wardley
Andrew M
AM
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D005260:Female; D006801:Humans; D017698:Postmenopause / Q000187:drug effects* / Q000378:metabolism
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal